I am supportive of doing something. I am actually not against this bill, but I think it's a piecemeal approach.
We need to get that done immediately. That will add significant resources to the two agencies, plus the appropriations p...
It is outrageous that we still have this practice going on where pharmaceuticals are paying their competitors to keep th...
This legislation addresses product hopping, a particular abusive form of conduct used by drug manufacturers to extend th...
Break them up. That is the remedy that I have advocated on some of the Big Tech companies.
I am also pleased to be in partnership with Representatives Johnson and Issa in a House companion to a bill.
Today, pharmaceutical companies are confronting the American people with a terrible choice: Miss rent payments and skip ...
You can't just do that and expect these healthcare pharma issues to be taken care of without funding those agencies.
to explicitly prohibit healthcare mergers that enable greater exploitation of existing market power and are likely to re...
I look forward to joining Mr. Issa in reforming our Nation's patent laws.
I think that regulatory reform and competition advocacy are very, very important.